IDeate-Esophageal01 is an international, multicenter, randomized Phase III study evaluating ifinatamab deruxtecan in patients with pretreated advanced or metastatic esophageal squamous cell carcinoma (ESCC). The primary objective is to assess the overall survival (OS) benefit of ifinatamab deruxtecan compared with investigator’s choice chemotherapy. Eligible participants are adults with advanced or metastatic ESCC who have received prior systemic therapy. Participants are randomized to receive either ifinatamab deruxtecan or investigator’s choice of chemotherapy, including agents such as paclitaxel, docetaxel, or irinotecan. The trial is conducted across multiple countries and sites. The primary endpoint is overall survival.
IDeate-Esophageal01 is an international Phase III clinical trial for people with advanced or metastatic esophageal squamous cell carcinoma. The study compares the investigational drug ifinatamab deruxtecan with standard chemotherapy. Adults whose cancer has previously been treated and has progressed may participate. The main goal of the study is to determine whether treatment with ifinatamab deruxtecan can improve overall survival compared with chemotherapy chosen by the treating physician. Participants are randomly assigned to one of the treatment groups. Researchers will then evaluate survival outcomes and the safety of the treatments.
